Skip to content

US · PHIO · BIOTECHNOLOGY

Phio Pharmaceuticals Corp. (PHIO) intrinsic value and stock valuation

$0.66as of 2026-11-21 · Mkt cap 12.43M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Phio Pharmaceuticals Corp. DCF and intrinsic value

InvestorsCraft values PHIO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PHIO’s statements →

Phio Pharmaceuticals Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology King of Prussia, PA 19406 phiopharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-8.7M
20112025
Free cash flow
-$-7.99M
20112025
Total equity
$20.2M+9.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-9.22M-$-7.39M-$-10.82M-$-11.46M-$-13.51M
Net income-$-8.7M-$-7.15M-$-10.83M-$-11.48M-$-13.29M
EPSd-$-1.45M-$-9.05M-$-47.09M-$-88.31M-$-110.75M
Operating cash flow-$-7.98M-$-7.11M-$-10.75M-$-12.13M-$-11.86M
Capital expenditure-$-10K-$0.00-$-10K-$-120K-$-50K
Free cash flow-$-7.99M-$-7.11M-$-10.75M-$-12.25M-$-11.91M
Total assets$21.5M$5.74M$9.36M$12.8M$25.2M
Total debt$0.00$0.00$40K$170K$290K
Net debt-$-21.03M-$-5.38M-$-8.46M-$-11.61M-$-23.76M
Total equity$20.2M$4.72M$7.73M$10.8M$21.9M
Cash and short-term investments$21M$5.38M$8.49M$11.8M$24.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$4.62M$3.64M$6.33M$7.01M$8.89M
Gross profit-$-4.62M-$-3.64M-$-6.33M-$-7.01M-$-8.89M
Research and development expenses$4.62M$3.64M$6.33M$7.01M$8.89M
Selling, general and administrative expenses$4.6M$3.74M$4.29M$4.45M$4.62M
Other expenses-$-4.62M-$-3.64M-$-6.13M-$-7.01M-$-8.89M
Operating expenses$4.6M$3.74M$4.49M$4.45M$4.62M
Cost and expenses$9.22M$7.39M$10.8M$11.5M$13.5M
Interest income$0.00$230K$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$180K$70K$70K
Ebitda-$-8.7M-$-7.15M-$-10.64M-$-11.41M-$-13.21M
Operating income-$-9.22M-$-7.39M-$-10.82M-$-11.46M-$-13.51M
Total other income/expenses, net$520K$240K-$0.00-$-20K$220K
Income before tax-$-8.7M-$-7.15M-$-10.83M-$-11.48M-$-13.29M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-8.7M-$-7.15M-$-10.83M-$-11.48M-$-13.29M
Weighted average shares outstanding$5.98M$790K$230K$130K$120K
Weighted average diluted shares outstanding$5.98M$790K$230K$130K$120K
Balance sheet
20252024202320222021
Cash and short-term investments$21M$5.38M$8.49M$11.8M$24.1M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$21.5M$5.74M$9.32M$12.5M$24.7M
Property, plant and equipment, net$10K$0.00$40K$340K$420K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$10K$0.00$40K$370K$440K
Total assets$21.5M$5.74M$9.36M$12.8M$25.2M
Accounts payable$430K$250K$660K$780K$280K
Short-term debt$0.00$0.00$40K$140K$120K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$430K$1.01M$1.63M$1.94M$3.07M
Long-term debt$0.00$0.00$0.00$40K$170K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$910K$0.00$0.00$40K$170K
Capital lease obligations$0.00$0.00$40K$170K$290K
Total liabilities$1.34M$1.01M$1.63M$1.97M$3.24M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-155.05M-$-146.36M-$-139.21M-$-128.38M-$-116.9M
Accumulated other comprehensive income (loss)$0.00$0.00-$0.00$0.00$0.00
Total equity$20.2M$4.72M$7.73M$10.8M$21.9M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$40K$170K$290K
Net debt-$-21.03M-$-5.38M-$-8.46M-$-11.61M-$-23.76M
Cash flow statement
20252024202320222021
Net income-$-8.7M-$-7.15M-$-10.83M-$-11.48M-$-13.29M
Depreciation and amortization$0.00$40K$180K$190K$70K
Stock-based compensation$480K$150K$300K$410K$480K
Change in working capital$230K-$-140K-$-540K-$-1.26M$990K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$180K-$-400K-$-120K$500K-$-450K
Net cash provided by operating activities-$-7.98M-$-7.11M-$-10.75M-$-12.13M-$-11.86M
Investments in property, plant and equipment-$-10K-$0.00-$-10K-$-120K-$-50K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K$10K-$-10K-$-120K-$-50K
Common stock issued$23.7M$4M$7.45M$0.00$19.6M
Common stock repurchased$0.00-$0.00-$-10K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$23.6M$4M$7.41M-$-30K$21.7M
Net change in cash$15.7M-$-3.11M-$-3.34M-$-12.28M$9.81M
Cash at end of period$21M$5.38M$8.49M$11.8M$24.1M
Operating cash flow-$-7.98M-$-7.11M-$-10.75M-$-12.13M-$-11.86M
Capital expenditure-$-10K-$0.00-$-10K-$-120K-$-50K
Free cash flow-$-7.99M-$-7.11M-$-10.75M-$-12.25M-$-11.91M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Phio Pharmaceuticals Corp.

        Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

        CEO
        Robert L. Bitterman
        Employees
        6
        Beta
        0.81

        Explore

        Frequently asked questions

        What is the intrinsic value of Phio Pharmaceuticals Corp. (PHIO)?

        InvestorsCraft does not currently publish an intrinsic value for PHIO. How the IC value is calculated.

        Is PHIO undervalued?

        InvestorsCraft does not publish an undervaluation signal for PHIO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.